ARTICLE | Company News
Medivation, University of California deal
September 26, 2005 7:00 AM UTC
MDVN acquired the university's MDVN 300 series of small molecule androgen receptor antagonists. MDVN plans to start clinical development of compounds to treat hormone-refractory prostate cancer (HRPC...